|
| Status |
Public on Jan 03, 2007 |
| Title |
A549 Low dose treatment group (100 nM). |
| Sample type |
RNA |
| |
|
| Source name |
NSCLC cell line
|
| Organism |
Homo sapiens |
| Characteristics |
See publication for details.
|
| Treatment protocol |
A549 Low dose treatment group (100 nM). 5-aza-2'-deoxycytidine qod for 6 days.
|
| Growth protocol |
See publication for details.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Trizol
|
| Label |
biotin
|
| Label protocol |
Affymetrix
|
| |
|
| Hybridization protocol |
please see the Southwestern Medical Center Microarray Core Facility website for details
|
| Scan protocol |
please see the Southwestern Medical Center Microarray Core Facility website for details
|
| Description |
A549 Low dose treatment group (100 nM).
|
| Data processing |
Raw signal data without normalization
|
| |
|
| Submission date |
Sep 06, 2006 |
| Last update date |
Aug 28, 2018 |
| Contact name |
David S Shames |
| E-mail(s) |
[email protected]
|
| Phone |
650-225-7559
|
| Organization name |
Genentech Inc
|
| Department |
Oncology Biomarker Development
|
| Lab |
Shames
|
| Street address |
1 DNA Way
|
| City |
South San Francisco |
| State/province |
CA |
| ZIP/Postal code |
94080 |
| Country |
USA |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE5816 |
A Genome-wide Screen for Hypermethylated Genes in Lung Cancer |
|
| Relations |
| Reanalyzed by |
GSE64985 |
| Reanalyzed by |
GSE119087 |
